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Summary
Increased Myc gene copy number is observed in human prostate cancer. To define Myc’s functional role, we generated
transgenic mice expressing human c-Myc in the mouse prostate. All mice developed murine prostatic intraepithelial
neoplasia followed by invasive adenocarcinoma. Microarray-based expression profiling identified a Myc prostate cancer
expression signature, which included the putative human tumor suppressor NXK3.1. Human prostate tumor databases
revealed modules of human genes that varied in concert with the Myc prostate cancer signature. This module includes
the Pim-1 kinase, a gene known to cooperate with Myc in tumorigenesis, and defines a subset of human, “Myc-like” human
cancers. This approach illustrates how genomic technologies can be applied to mouse cancer models to guide evaluation
of human tumor databases.
Introduction of Myc in human prostate cancer remains undefined. Numerous
studies of human prostate cancer have demonstrated increased
The mouse has long been exploited as a model to study the Myc gene copy number in up to 30% of tumors, even at the
molecular basis of human cancers and test novel therapies. preneoplastic stage called prostate intraepithelial neoplasia
(PIN) (Jenkins et al., 1997; Nesbit et al., 1999; Qian et al., 1997;Recent advances in mouse engineering techniques and in geno-
mics tools to query mouse tumor tissue allow a more global Sato et al., 1999), but this finding is not conclusive because
Myc is one of many genes localized to this 8q24 amplicon (Elocomparison of these models to human cancer. We have ad-
dressed this issue in a novel transgenic model of mouse prostate and Visakorpi, 2001).
Efforts to define the mechanism by which Myc induces can-cancer using the human Myc gene as the initiating event. Myc
has been widely implicated in many human cancers (Nesbit et cer have identified a number of effects such as increased cell
proliferation, which clearly contribute to tumorigenesis. Amongal., 1999) and is sufficient to give cancer phenotypes in various
murine tissues when expressed as a transgene (Jensen et al., the most perplexing has been the well-documented proapoptotic
activity of Myc, particularly when serum or other survival factors2002; Moroy et al., 1991; Nesbit et al., 1999; Pelengaris et al.,
1999, 2002a, 2002b; Zhang et al., 2000b). We focused our are limiting (Ahmed et al., 1997; Evan et al., 1992; Pelengaris
et al., 2002b; Prendergast, 1999). Recent transgenic modelsstudies on the role of Myc in prostate cancer for two reasons.
First, several independent, publicly available gene expression have clarified how the seemingly paradoxical death-promoting
activity of Myc can lead to cancer. Expression of a hormone-profiling datasets of human prostate tumors (Dhanasekaran et
al., 2001; Singh et al., 2002; Welsh et al., 2001) are available regulated Myc transgene in the skin rapidly induces epidermal
hyperplasia and papillomas, with associated increases in cellu-for comparison to mouse models. Second, the functional role
S I G N I F I C A N C E
Previous attempts to model human prostate cancer by manipulating expression of genes implicated in human tumors have fallen
short, in that most fail to give invasive carcinomas. Here we demonstrate that mice expressing human Myc in the prostate reliably
develop murine prostatic intraepithelial neoplasia, then invasive adenocarcinomas. These tumors share molecular features with
human prostate cancer, as defined by array-based expression profiling, such as loss of the candidate human prostate tumor
suppressor gene Nkx3.1 and upregulation of the serine/threonine kinase Pim-1. This model provides a novel tool for identification
and functional evaluation of genetic events in prostate cancer progression and for preclinical therapeutic studies.
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Figure 1. Generation and characterization of
Myc transgenic mice
A: Construction of the Lo-Myc and Hi-Myc trans-
gene. cDNA encoding human c-Myc was
cloned along with the insulin polyA site down-
stream of either the rat probasin or the modified
small composite probasin promoters. Primers
specific to each promoter and human Myc were
used to confirm germline transmission of the
transgene.
B: Comparative expression of Myc in the mouse
prostate. Total protein was isolated from 2- and
4-week-old wild-type, Hi-Myc and Lo-Myc mice.
Myc expression was determined by Western blot
using the human-specific -9E10 Myc antibody.
Transgene expression is seen as early as 2 weeks
in both transgenic mice, and expression in-
creases as mice reach puberty by 4 weeks.
-actin was used as a loading control.
C: Kinetics of mPIN and cancer progression in Hi-
Myc and Lo-Myc transgenic mice. Low (100)
and high (400) magnification views of the dor-
solateral prostate are shown. Hi-Myc mice exhibit
mPIN as early as 2 weeks (m and p) compared
to 4 weeks (h and k) in the Lo-Myc transgenic
animals. Hi-Myc mice go on to develop invasive
prostatic adenocarcinoma by 6 months (o and r)
whereas the Lo-Myc animals continue to exhibit
mPIN at the same time point (i and l). Arrows
indicate nuclear atypia.
lar proliferation and minimal evidence of apoptosis (Pelengaris of insulin-producing islet cells, due to increased apoptosis, and
subsequent onset of diabetes (Pelengaris et al., 2002a, 2002b).et al., 1999, 2002a). However, these tumors rapidly apoptose
when cultured ex vivo, presumably due to the lack of critical When complemented with a BclXL transgene, the mice no longer
display the apoptotic phenotype, but develop aggressive islet cellsurvival factors present in the mouse dermis. In contrast, trans-
genic expression of Myc in the pancreas causes rapid involution cancers. These experiments demonstrate that the response to Myc
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Figure 2. Development of cancer in Hi-Myc and
Lo-Myc transgenic animals without neuroendo-
crine differentiation
A: Longer latency for cancer progression in Lo-
Myc mice. Dorsolateral lobes from 6 and 12
month transgenic mice reveal invasive adeno-
carcinoma at 12 months in the Lo-Myc animals
(a–d). In contrast, invasive tumor is already ap-
parent by 6 months (e and g) in the Hi-Myc mice.
Arrows depict nuclear atypia associated with
mPIN and cancer.
B: Presence of an intact fibromuscular layer and
basement membrane, as shown by the positive
SMA and laminin immunostaining (arrows, a and
b), confirms the in situ nature of the mPIN lesions.
In contrast, SMA and laminin staining are absent
in the invasive tumors (c and d). Contractile
smooth muscle surrounding blood vessels serve
as internal positive controls (arrows, c and d).
C: Tumors do not undergo neuroendocrine
differentiation. Synaptophysin immunostaining
identifies the rare neuroendocrine cell normally
present in murine prostates (a, arrow). The Hi-
Myc prostate with invasive adenocarcinoma
shows no synaptophysin staining (b) whereas the
dorsolateral lobes of the LADY mice stain positive
(c). Images depict the dorsolateral lobes.
expression in different tissues is critically dependent on associated preneoplastic phenotype in the prostate. These cells demon-
strated a high rate of proliferation that overcame the apoptoticsurvival signals and suggest a role for secondary cooperating
effect of Myc expression, suggesting that prostate tissue con-events in rescuing cells from Myc-induced apoptosis.
tains survival factors that allow the cells to tolerate increasedTo determine the consequence of increased c-Myc expres-
Myc protein. Microarray expression profiling studies defined asion in the prostate, we generated transgenic mice expressing
Myc prostate cancer expression signature that shares featureshuman c-Myc from two different strength prostate-specific pro-
with human prostate cancer and implicates candidate genes
moters. In all founder lines, Myc expression resulted in complete in tumor progression. For example, expression of the putative
penetrance of mouse prostatic intraepithelial neoplasia (mPIN), human prostate tumor suppressor gene NXK3.1 (Bowen et al.,
which progressed to invasive adenocarcinoma within 6 to 12 2000; He et al., 1997; Voeller et al., 1997) was detected in Myc-
months of age. mPIN lesions were observed as early as 2 to 4 induced mPIN lesions but absent in invasive cancers. Further-
more, analysis of human cancer databases with the murine Mycweeks, providing evidence that Myc is sufficient to induce a
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Table 1. High penetrance of mPIN and cancer in Myc transgenic mice
A. Penetrance in Myc transgenic mice
Strain Age # Mice Phenotype Comments
Hi-Myc 3 months 16 16/16 mPIN mPIN in 4/4 mice at 2 weeks
6 months 20 19/20 invasive cancer
1/20 mPIN*
Lo-Myc 10 months 10 8/10 mPIN* 2 mice at 2 weeks were benign
10 months 10 10/10 invasive cancer
B. Timing of mPIN and cancer progression in Myc transgenic mice
mPIN mPIN/cancer transition Invasive cancer
Hi-Myc 2 weeks 3 to 6 months 6 months
Lo-Myc 4 weeks 6 to 12 months 12 months
Mice were aged to the appropriate time point and sacrificed for histological analysis. Age, phenotype, and number of mice are listed for both the Hi-
Myc and Lo-Myc transgenic models. Generally, in the Hi-Myc model, all mice 3 months developed mPIN and all animals older than 6 months developed
cancer. In the Lo-Myc model, most animals less than 12 months developed mPIN and cancer after 1 year. Only a few exceptions (*) are observed.
gene signature uncovered gene clusters whose expression was previously shown to cooperate with Myc in mouse tumor mod-
els. Collectively, these findings define a novel transgenic mousetightly correlated in human prostate, breast, and ovarian cancer.
The murine Myc prostate tumor signature genes that are most model of prostate cancer and demonstrate the utility of compar-
ing mouse and human cancer expression databases.consistently coexpressed in the human cancers included Pim-1,
Figure 3. Myc expression gives a proliferative ad-
vantage to prostate tissue
A: Ki67 and TUNEL labeling revealed an increase
in both proliferation and apoptosis as cells pro-
gress from wild-type (a and d) to mPIN (b and
e) and finally to invasive cancer (c and f). Images
of the dorsolateral lobes are shown.
B: Proliferation increases as mice develop pros-
tate cancer. A total of 500 cells were counted
from five high-power fields and the number
of Ki67-positive cells (proliferative index) was
scored and graphed.
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Results
Transgenic expression of Myc in the prostate induces
mPIN, then invasive adenocarcinoma with
reproducible kinetics and high penetrance
Two different prostate-specific transgenic expression con-
structs (probasin-Myc and ARR2/probasin-Myc) were used to
vary the dosage of Myc expression specifically in the prostate
(Figure 1A). Expression from the probasin promoter begins at
a low level in the prostate at 1 to 2 weeks of age and increases
with rising levels of androgen as the mice reach puberty between
4 and 8 weeks (Figure 1B). The ARR2/probasin promoter con-
tains two additional androgen response elements, which boost
the level of androgen-dependent expression (Figure 1B) (Wu et
al., 2001; Zhang et al., 2000a). Multiple founders were obtained
for each construct (seven from the ARR2/probasin-Myc and three
from the probasin-Myc), prostate-specific Myc protein expression
was confirmed, and independent lines from each construct were
expanded for phenotypic analysis. Based on the levels of trans-
gene expression, the probasin-Myc mice and ARR2/probasin-Myc
mice were designated Lo-Myc and Hi-Myc, respectively.
Mouse PIN (mPIN) is characterized histologically by the
presence of multifocal proliferative lesions of atypical epithelial
cells affecting several existing ductules within individual lobes.
mPIN usually displays distinctive architectural growth patterns,
e.g., cribiform and/or tufting, but these cells must also exhibit
progressive nuclear atypia. Atypical cells are characterized by
the presence of large irregular nuclei, exhibiting hyperchromatic
or vesicular chromatin patterns, with prominent nucleoli and
amphophilic cytoplasm. In both the Lo-Myc and Hi-Myc mice,
multifocal proliferative lesions affecting several ductules within
the individual lobes were observed in the dorsolateral (Figures
1Ck, 1Cl, 1Cp, and 1Cq) and ventral lobes and to a lesser extent
in the anterior lobe. Cribiform and tufting growth patterns of the
secretory epithelial layer were also observed (Figures 1Ck, 1Cl,
1Cp, and 1Cq) as well as progressive nuclear atypia (Figure 1C,
Figure 4. Vascular profile of myc tumorsarrows), distinguishing these lesions from benign hyperplasia.
Finally, the in situ nature of these lesions was confirmed by the Mice were injected with FITC-conjugated Lycopersicum esculentum lectin
that binds to the luminal surface of blood vessels (in green). Topo 3 waspresence of an intact basement membrane and fibromuscular
also used for visualization of nuclei (in blue). A–C: Wild-type animals (A, 2layer, as demonstrated by positive laminin and smooth muscle
month; B and C, 1 year). Note that the blood vessels travel in the stroma
actin (SMA) immunohistochemical staining, respectively (Fig- justaposed to the prostate epithelium. There is no increase in vascular den-
ures 2Ba and 2Bb). sity in the prostate of 2-month-old versus 1-year-old wild-type mice; D–F:
Transgenic animals (2 months). Increased vascular density and tortuosity inThe mPIN lesions in both Lo-Myc and Hi-Myc mice subse-
vessels is associated with early transformation stages; G–I: In transgenicquently progressed to invasive adenocarcinomas, as seen by
animals (1 year), higher degrees of vascular density and disorganization
the extension of numerous nests of acini consisting of cytologi- characterize late-stage tumors. Each panel represents a different animal.
cally atypical cells into the prostatic stroma and periprostatic In each case, the anterior lobe was photographed. J: Table showing the
vascular density (mm2) in Hi-Myc and control littermates.adipose tissue. These acini exhibit crowding, irregular contours
and haphazard growth patterns (Figures 1Co and 2Ab, 2Ae,
and 2Af). The mPIN/cancer transition was evident by 3 to 6
months in all lobes of the Hi-Myc mice and by 10 to 12 months
model for studying progression from mPIN to cancer and forin the Lo-Myc mice, suggesting that the dosage of Myc may
preclinical therapeutic studies.affect the rate of disease progression (Figure 2A). Invasion was
To date, the only known murine models of prostate cancerconfirmed by the absence of laminin and SMA staining, which
that progress beyond the mPIN stage are the SV40 large Tdocuments penetration through the basement membrane and
antigen models of prostate cancer (TRAMP, C3-Tag, and LADY)the fibromuscular layer, respectively (Figures 2Bc and 2Bd).
(Garabedian et al., 1998; Greenberg et al., 1995; Kasper et al.,Foci suggestive of lymphovascular invasion were also noted in
1998; Masumori et al., 2001; Shibata et al., 1996). One potentialsome cancers (data not shown). mPIN was always found in
shortcoming of the T antigen models is the high frequency ofglands adjacent to the invasive tumor. The penetrance of mPIN
neuroendocrine differentiation that occurs, as recognized byand cancer was essentially 100 percent in all founder lines with
reliable kinetics (Table 1), indicating the potential utility of this its typical histologic features and subsequent confirmation by
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Figure 5. Effects of castration on Myc-induced mPIN and prostate cancer
A: Schematic of castration experiment using the Hi-Myc transgenic mice. Mice were either castrated at 2 months of age with mPIN (n  3) or castrated
at 8 months after tumors had developed (n  9) and then sacrificed 1, 3, or 5 months post-surgery (*). Prostate lobes were microdissected and analyzed
by H&E.
B: Castration causes the reversion of mPIN lesions 1 month post-surgery (a–c). Castration at later time points results in partial regression of the primary
tumors, when examined at 1 (d–f), 3 (g–i), and 5 (j–l) months post-surgery. In each panel, images depict H&E stains of the dorsolateral lobes of the prostate.
C: Residual, nonproliferating tumor remains following castration. Immunohistochemistry using -Ki67 shows a decrease in the number of Ki67-positive cells
following castration (compare a and b). Immunohistochemistry using the -androgen receptor (AR) antibody also shows a decrease in the number of AR-
positive cells as well as an increase in cytoplasmic staining post-surgery (compare c and d). Images represent the dorsolateral lobes.
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immunohistochemical stains such as synaptophysin or chro- regulated by androgen, interpretation of the effect of hormone
ablation must consider potential effects on expression of themogrannin A (Figure 2Cc) (Masumori et al., 2001). Although
human prostate cancers can occasionally possess a completely transgene. Mice were either castrated at 2 months when they
had definite mPIN lesions (n  3) or at 8 months (n  9) afterneuroendocrine phenotype (e.g., small cell carcinoma), the ma-
jority do not. The mPIN and invasive carcinoma lesions detected tumors had developed, then analyzed either 1, 3, or 5 months
post-castration (Figure 5A). All mice castrated at 2 months ofin the Lo-Myc and Hi-Myc mice do not exhibit the morphologic
features of neuroendocrine carcinomas, and this is further con- age have complete regression of mPIN within one month of
castration (Figures 5Ba–5Bc). This was correlated with absencefirmed by the lack of immunostaining with synaptophysin (Figure
2C, compare b and c). Therefore, the Lo- and Hi-Myc mice of detectable transgene expression by immunoblot (Figure 5D).
This result indicates that Myc-induced mPIN is reversible, similarrepresent novel models for human prostatic adenocarcinoma
that may offer advantages over current models. to other Myc-induced neoplastic phenotypes in tetracycline-
regulated models (Jain et al., 2002; Karlsson et al., 2003). Simi-
larly, all mice with prostate cancer (castrated at 8 months ofMyc expression in the mouse prostate induces
proliferation, apoptosis, and angiogenesis age) had histologic evidence of regression and fibrosis at all
time points post-castration (Figures 5Bd–5Bl). However, unlikeMyc can induce proliferation, apoptosis, and angiogenesis in
many cell types (Amati et al., 1998; Dang, 1999; Pelengaris et mPIN lesions (Figures 5Ba–5Bc), all these mice had residual
tumor present even 5 months post-castration (Figures 5Bk andal., 2002a, 2002b; Prendergast, 1999; Watnick et al., 2003). To
understand the cellular effects of Myc overexpression in the 5Bl). The residual tumors were apparently quiescent since we
were unable to document proliferation of tumor cells by nuclearprostate, we first tested for proliferation using Ki67 immunohis-
tochemistry and apoptosis using TUNEL assays. Immunohisto- Ki67 staining (Figures 5Ca and 5Cb). Immunoblot studies
showed loss of Myc expression in the residual tumors, indicatingchemistry showed an increase in Ki67 staining in both mPIN
and tumor lesions when compared to wild-type samples, as silencing of the transgene. Also, these tumors expressed lower
levels of AR protein, a known consequence of castration (Figureshown in Figure 3A (d–f). Ki67 staining was quantified by count-
ing a total of 500 cells. The proliferative index increased from 5D). Following castration, we also observed weak heterogenous
expression of AR with predominately cytoplasmic localization,20 in wild-type cells to 140 in mPIN lesions and 180 in tumor
tissue (Figure 3B). TUNEL assays performed on the same tumor compared to nuclear localization in the intact mice (Figure 5C,
compare c and d). Collectively, these findings establish that ARshowed that Myc was also capable of inducing apoptosis in
the mouse prostate (Figures 3Aa–3Ac). These results demon- is inactive and the Myc transgene is not expressed in these
residual, post-castration tumors. The fact that these tumors failstrate that Myc induces both proliferation and apoptosis in the
mouse prostate; however, the rapid development of mPIN sug- to fully regress, unlike the mPIN lesions, suggests that additional
genetic events may have occurred that maintain tumor cell sur-gests that, like epidermal cells (Pelengaris et al., 1999), the
prostate may contain survival signals that rescue much of the vival. Larger cohorts of mice will be followed for longer time
intervals to determine if these mice eventually relapse with pro-gland from Myc-induced apoptosis.
Myc can also induce angiogenesis in certain tissues, a prop- gressive, hormone refractory prostate cancer.
erty that likely contributes to tumor progression and metastasis
(Elenbaas et al., 2001; Hurlin et al., 1995; Pelengaris et al., 1999; An expression signature for Myc-driven murine
prostate cancerWatnick et al., 2003). Therefore, we characterized changes in
vascular density in the Hi-Myc tumor model at the mPIN and The high penetrance and reliable kinetics of the PIN/cancer
transition in these Myc models provides an experimental oppor-invasive cancer stages, using wild-type and transgenic animals
at 2 and 12 months of age (Figures 4A–4I). Blood vessels were tunity to define the cooperating molecular events involved in
Myc-driven prostate cancer progression. We isolated dorsal,identified in green after perfusion with FITC-conjugated Lyco-
persicum esculentum lectin as previously described (Rodriguez- lateral, ventral, and anterior prostate lobes from Hi-Myc trans-
genic mice and nontransgenic littermate controls at various timeManzaneque et al., 2001). Increased vascular density was de-
tected as early as 2 months in transgenic animals with mPIN points during the mPIN/cancer transition for gene expression
profiling experiments. Samples were divided for parallel analysis(Figures 4D–4F and 4J), and vascular density doubled with pro-
gression to invasive adenocarcinoma at the 12 month time point by mouse Affymetrix arrays for gene expression and compara-
tive genome hybridization arrays (array CGH) for chromosomal(Figures 4G–4I and 4J). Vascular alterations, such as tortuosity
and disorganization of vessels common to tumors, were noted at gains and losses. Matched tissue was saved for histological
and immunohistochemical studies. The expression signatures2 months and became significantly pronounced by 12 months.
Effects of hormone ablation on the initiation and for wild-type and transgenic (mPIN and cancer combined) were
strong enough to be recognized by unsupervised clustering withmaintenance of Myc-induced prostate lesions
Since hormone ablation therapy is the primary clinical treatment only one error (Figure 6A). Parallel array CGH experiments were
also conducted using genomic DNA from these samples tofor prostate cancer patients with advanced stage disease, we
examined the effect of castration on disease progression in look for evidence of chromosomal gains or losses that might
accompany these expression changes. To date, we have notthe Hi-Myc transgenic mice. Since the ARR2PB promoter is
D: Myc transgene expression is turned off and AR levels decrease following castration. Immunoblots of prostate lysates isolated from wild-type or transgenic
intact (I) or castrate (C) mice were performed using the -Myc (9E10) and -AR antibodies. All mice showed a loss of Myc expression following castration
as well as a decrease in AR levels. Actin serves as a loading control.
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Figure 6. Microarray analysis identifies a distinct expression signature of genes in Myc transgenic animals
A: Unsupervised clustering classifies samples as either wild-type (wt) or transgenic (mPIN and cancer) with one exception. The raw gene expression data
is available at http://doe-mbi.ucla.edu/myc_driven_prostate_cancer/.
B: Genes differentially expressed between wild-type and transgenic mice. The top 60 non-EST genes are included, and a full list is available in the Supplemental
Data on the Cancer Cell website. The list includes two genes known to be involved in human prostate cancer, Nkx3.1 and Pim-1 (arrows). Nkx3.1 expression
is lost in transgenic samples and Pim-1 is upregulated consistent with published human data (Bowen et al., 2000; Dhanasekaran et al., 2001). Expression
values of each gene are normalized to have a mean of zero and standard deviation of one across the samples.
C and D: Nkx3.1 protein levels diminish in mPIN lesions and are lost in tumors samples consistent with microarray data. Immunohistochemistry shows a
variable level of Nkx3.1 in mPIN lesions that is completely absent in tumors (C, compare panels b and c to d). Western blot analysis using the Nkx3.1 antibody
shows a consistent loss of Nkx3.1 expression as tumors progress from mPIN lesions (D). The dorsolateral lobes are depicted in each image.
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Figure 7. Cross-species expression module com-
parison algorithm
A: Schematic of the computational algorithms
used to identify genes consistently regulated in
Myc transgenic and human prostate cancers
based on predicted Myc status (blue path) or
Myc expression levels (red path) (see Experimen-
tal Procedures).
B: Scatter plot showing the genes differentially
expressed between Myc-like and non-Myc-like
human tumors in multiple datasets. In the graph,
each point represents a gene found in the Pros-
tate A-C (Dhanasekaran et al., 2001; Singh et al.,
2002; Welsh et al., 2001) human cancer datasets.
For each gene, the Student t test p values re-
flecting the degree of differential gene expres-
sion between Myc-like and non-Myc-like human
tumors were determined and plotted (see sche-
matic, panel A). The top 10 entries from Table
2A are indicated by yellow and red (Pim-1) dia-
monds.
observed any genomic changes in mPIN lesions or cancers, Additionally, the transgenic Myc gene list can include Myc tran-
scriptional targets or genes whose up- or downregulation com-but it is important to note that current mouse BAC arrays are
limited to 3 Mb resolution and we cannot rule out smaller gains plements Myc expression during tumorigenesis. Since the Myc
transgene is expressed as early as 1 to 2 weeks of age, theor losses (data not shown).
Next we generated a supervised gene list that distinguishes transgenic Myc gene list can include genes directly or indirectly
regulated by Myc transcription. In an attempt to address thiswild-type mice from Myc transgenic mice. We ranked genes by
the degree of differential expression between wild-type and issue, we compared our list of Myc-driven tumor-associated
gene changes to various lists of Myc target genes and foundtransgenic mice using the Student’s t test. The 60 most differen-
tially expressed genes, excluding ESTs, are shown in Figure that some genes and gene families are in common, but we were
unable to demonstrate any statistically significant overlap. Thus,6B, and the complete list is available as Supplemental Data
at http://www.cancercell.org/cgi/content/full/4/3/223/DC1. The not unexpectedly, our list does not appear to be dominated by
direct Myc transcriptional targets. A better distinction betweengenes on this list can potentially come from several categories,
including genes modulated generally in tumorigenesis (e.g., Myc primary and secondary target genes and genes more gen-
erally associated with prostate cancer will be possible by futurefrom expansion of a particular cell type) or specifically in prostate
tumorigenesis or Myc-driven tumorigenesis (Coller et al., 2000). comparison of the Myc-driven tumors to other mouse prostate
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cancer models (Wu et al., 2003 [this issue of Cancer Cell]). signature (Figure 6B) in a gene expression-based class predic-
The substantial role of Myc in cellular proliferation (Gartel and tion analysis (Golub et al., 1999), and then identified the genes
Shchors, 2003; Sears and Nevins, 2002) raises the possibility most consistently differentially expressed between Myc-like and
that the Myc prostate expression signature is strongly com- non-Myc-like human tumors and between wild-type and Myc
prised of genes associated with proliferation. However, a com- transgenic mouse prostates (Figure 7A, blue path) as follows: (a)
parison of the Myc prostate signature with several previously We began with our list of genes differentially expressed between
published proliferation signatures did not show statistically sig- wild-type and Myc transgenic mice. We then identified the hu-
nificant overlap (Lam et al., 2001; Perou et al., 1999; Rosenwald man orthologs for these genes using the HomoloGene database
et al., 2003; Whitfield et al., 2002). (http://www.ncbi.nlm.nih.gov/HomoloGene/) and determined
Several genes of interest appeared on the list and include which were present in three human prostate cancer gene ex-
L-Myc, normally expressed at high levels in differentiated pros- pression datasets. (b1) We ascertained whether the human tu-
tate tissue (Luo et al., 2001), Tmprss2, a serine protease overex- mors were more Myc-like or non-Myc-like using a weighted
pressed in a majority of prostate cancer patients (Vaarala et gene voting prediction algorithm (Golub et al., 1999) and then
al., 2001), Sparc, an antiadhesive protein that is differentially (c) made ranked lists of the genes most differentially expressed
expressed during human prostate cancer progression (Thomas between the human tumors in these two categories using the
et al., 2000), EGF, which has been implicated in prostate cancer Student’s t test. Finally, (d) we identified the genes most consis-
progression (Kim et al., 2003), and several Ly6 genes that belong tently differentially expressed between Myc-like and non-Myc-
to the same family as prostate stem cell antigen (PSCA), a cell like human tumors based on the overlap between the ranked
surface antigen overexpressed in human prostate cancer (Jalkut lists from the mouse and the three human datasets. In summary,
and Reiter, 2002) (Figure 6B, asterisks). We focused our atten- this method investigates whether the coexpressed mouse Myc
tion on two genes, Nkx3.1 and Pim-1, for the reasons discussed prostate signature genes are also coexpressed in human can-
below (Figure 6B, arrows). cers and identifies the most consistently regulated genes in the
Myc prostate tumor expression module.
Loss of Nkx3.1 protein expression marks the transition We first performed this analysis using three publicly available
from mPIN to invasive cancer prostate cancer datasets (Dhanasekaran et al., 2001; Singh et
The microarray finding of reduced levels of Nkx3.1 mRNA in al., 2002; Welsh et al., 2001). The most striking result was the
transgenic mice is of particular interest because human Nkx3.1 presence of Pim-1 at the top of our list (Table 2A, Figure 7B).
is a putative tumor suppressor gene in human prostate cancer
Pim-1 was on our original list of genes differentially expressed
(He et al., 1997). Loss of heterozygosity at the Nkx3.1 locus
between wild-type and Myc transgenic prostates with a rank of
occurs commonly in human prostate tumors due to large dele-
113 (Figure 6B; Supplemental Data on Cancer Cell website).tions at 8p22, but it has proved difficult to directly implicate
The reprioritization of Pim-1 to a rank of 1 is noteworthy, in thatNXK3.1 as the relevant gene since mutations do not occur in
Pim-1 has previously been shown to cooperate with Myc inthe remaining allele (Voeller et al., 1997). To distinguish between
lymphomagenesis (van Lohuizen et al., 1989, 1991), and sug-the possibilities that Nkx3.1 may be a Myc target gene (since
gests that this approach could be used with other transgenicdecreased Nkx3.1 mRNA levels were found in transgenic mice
cancer models and human datasets to identify complementingwith mPIN and cancer as compared to wild-type controls) versus
oncogenes.a complementary secondary event, we examined Nkx3.1 protein
To investigate whether the Myc expression signature identi-expression in situ using immunohistochemical studies. Nkx3.1
fied using our transgenic mice is prostate specific, we addedprotein expression was consistently present in mPIN lesions at
breast and ovarian cancer datasets to our cross-species com-variable levels (Figures 6Cb and 6Cc), but was undetectable in
parison algorithm. We again found that one of the most consis-all the cancers isolated from both the Hi-Myc and Lo-Myc strains
tently regulated genes in the Myc expression module is Pim-1(Figure 6Cd). Immunoblot studies of prostate lysates from tu-
(data not shown). This result is consistent with the fact that Mycmor-bearing mice also showed a marked decrease in Nkx3.1
expression is implicated in the progression of many tumor typesprotein expression when compared to lysates from wild-type
(Nesbit et al., 1999).or mPIN mice (Figure 6D). These results indicate that Nkx3.1
In the second method, we inferred the Myc status of theloss is distinct from the onset of Myc expression and raise
human tumors based on whether their Myc expression levelthe possibility that Myc gain and Nkx3.1 loss may be critical
was above or below the mean Myc expression level for thecooperating events in the mPIN/prostate cancer transition.
dataset (step b2) and then followed the rest of the procedure
outlined above (Figure 7A, red path). This procedure resultedCross-species bioinformatic comparison of mouse
in slightly different groupings of the human samples and accord-and human datasets implicates Pim-1 in
ingly a slightly different list of consistently modulated genesMyc-associated cancer progression
(Table 2B). It remains to be determined from independent dataThe large number of genes in the Myc prostate signature empha-
(e.g., Myc gene amplification status of human tumors) whethersizes the need for strategies to prioritize genes for functional
the predicted Myc status from the Myc mouse prostate tumorevaluation. Accordingly, we used two related methods to search
signature or the inferred Myc status from the Myc expressionfor gene expression patterns common to both our Myc trans-
levels better reflects the true Myc status of human tumors.gene model and human prostate cancer. A schematic of our
However, both methods result in Pim-1 and GNAS1 (G protein,“cross-species expression module comparison” approaches is
 stimulating activity polypeptide 1) in the top 10 of the list ofshown in Figure 7A.
consistently modulated genes. Additionally, this second methodIn the first method, we predicted the Myc status of the
human tumors using the genes from the Myc mouse prostate revealed two other genes previously implicated in either prostate
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cancer, PTOV1 (prostate tumor overexpressed gene 1), or Myc sion of Nkx3.1 in Myc-induced prostate tumors. Our immunohis-
function, ID3 (inhibitor of DNA binding 3) (Lasorella et al., 2001). tochemical results clearly demonstrate that Myc expression and
Nkx3.1 loss are distinct events, separated in time during the
Discussion mPIN/cancer transition. Of note, our finding appears distinct
from the Nkx3.1 loss associated with PTEN loss in the accompa-
The Myc transgenic models of prostate cancer described here nying paper (Wu et al., 2003) where reduced Nkx3.1 expression
offer several advantages over current models in which the SV40 is coincident with PTEN loss, implying coordinate regulation in
large T antigen serves as the initiating event. First, the histologic a single pathway. One compelling explanation for our result is
features of the mPIN and cancer lesions accurately reflect the that loss of Nkx3.1 complements increased Myc expression to
predominant adenocarcinoma phenotype observed in human promote the mPIN/cancer transition. Two additional findings
prostate cancer, with no evidence for the neuroendocrine phe- support this hypothesis. First, comparative genomic hybridiza-
notype observed in many of the T antigen models (Masumori tion studies of human prostate cancer often report the parallel
et al., 2001; Perez-Stable et al., 1997). Second, the fact that presence of chromosome 8q24 gain (Myc) and 8p22 loss
mPIN lesions appear with essentially 100 percent penetrance (Nkx3.1) in the same tumor (Tsuchiya et al., 2002). Second,
and progress to invasive cancer with reliable kinetics should
Nkx3.1 knockout mice develop mPIN lesions but not cancer,
make this model suitable for preclinical therapeutic studies. In
suggesting that a rate-limiting second hit may be required foraddition, the differences in progression time between the Lo-
full-blown tumorigenesis (Abdulkadir et al., 2002; Bhatia-GaurMyc and Hi-Myc models provides some flexibility in the design
et al., 1999; Kim et al., 2002). Alternatively, absence of Nkx3.1of secondary genetic mouse crosses to study the effects of
expression may be a marker for the cell of origin in the Myccomplementing events. Finally, these mice show considerable
and PTEN prostate cancer models and play no functional roleimprovement to the previously described Myc transgenic mouse
in the transformation process. These and other hypotheses candriven by the C3 promoter. While the Myc transgenic mice driven
now be tested through genetic crosses.by the PB and ARR2PB promoters develop mPIN and cancer,
In addition to examining our mouse prostate cancer genethe C3-Myc mouse fails to develop a similar phenotype, most
lists for known human prostate cancer orthologs, we askedlikely due to inadequate transgene expression (Zhang et al.,
whether the Myc prostate tumor signature can be observed in2000b).
a subset of human prostate cancers. Despite current limitationsOne notable feature of the mPIN lesions observed in our
due to different microarray expression profiling platforms andmodels is their rapid onset relative to the timing of transgene
the limited number of orthologs represented on mouse andexpression. This raises the possibility that Myc is sufficient to
induce preneoplastic lesions in the mouse prostate in the ab- human chips, we were able to verify that genes correlated with
sence of any secondary changes, consistent with reports of Myc status in the mouse can be used to define Myc-like human
Myc gene amplification in human PIN lesions (Bubendorf et al., tumors and that at least one of the genes most consistently
1999; Jenkins et al., 1997; Qian et al., 1997). The latency for associated with the Myc prostate tumor signature in human
disease onset in other transgenic Myc cancer models varies tumors, Pim-1, is consistent with our knowledge about the role
widely and presumably reflects the availability of cooperating of Myc in tumorigenesis. Pim-1, a serine/threonine kinase, is
survival signals, as seen in the skin versus pancreatic islet cell known to cooperate with Myc in murine lymphoma models
models discussed previously (Pelengaris et al., 1999, 2002b). (Moroy et al., 1991; van Lohuizen et al., 1989), and increased
Further work with an inducible Myc transgene is required to Pim-1 expression was recently observed in a subset of human
directly address this question. Unfortunately, exogenously ex- prostate cancers and shown to correlate with poor clinical out-
pressed hormone-regulated Myc fusion genes cannot be used come (Dhanasekaran et al., 2001). Although these investigators
due to confounding effects of currently available inducing did not determine the Myc status of these tumors, our mouse
agents such as tamoxifen on prostate cells. model and subsequent analysis of human microarray datasets
There is optimism in the mouse modeling community that suggest that these genes are linked in prostate and other cancers.
genetically engineered mouse models of human cancer will have
While our initial analysis demonstrates the utility of cross-
utility in the preclinical evaluation of new anticancer agents,
species comparisons of global datasets, a number of stepsperhaps serving as better predictors of clinical activity in hu-
need to be taken to realize the full potential of this approach.mans. We explored this question using hormone ablation ther-
It will be important to standardize expression analysis platformsapy, a conventional treatment approach for advanced prostate
to provide comprehensive coverage of the mouse and humancancer. The initial results establish that mPIN lesions are com-
transcriptome with appropriate cataloguing of orthologs forpletely reversible whereas advanced adenocarcinomas undergo
cross comparison. In addition, human datasets must be linkedpartial regression. Further studies are needed to determine if
to independent tissue analysis for specific molecular lesions ofmice with residual, apparently quiescent lesions eventually re-
interest, such as Myc amplification or PTEN loss for the exam-lapse with full-blown hormone refractory prostate cancer. It will
ples discussed here. Parallel construction of tissue arrays fromalso be of interest to determine why these advanced lesions,
tumor samples analyzed by expression microarrays will allowunlike mPIN, are not fully reversible despite silencing of the
such experiments to be performed. Ultimately, we envision us-transgene.
ing such cross-species comparisons to validate the relevanceAnother desired characteristic of mouse cancer models is
of mouse models for human disease, to help prioritize lengthythat they recapitulate the molecular features of the human dis-
gene lists for functional evaluation, and to extend lists of geneease. Mouse-specific genomics tools for expression profiling
cohorts that segregate with a specific molecular lesion acrossallowed us to address this question using a global approach.
Among the most interesting initial findings was reduced expres- multiple tissues.
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Experimental procedures and sterile dissecting shears were used to make a 4–5 mm incision in this
region. Using two sterile forceps, the testes were located and a ligature was
made around the testicular vessels and the tunica albugenea that encasesPlasmids
The plasmids ARR2PB-Flag-Myc-PAI and PB-Flag-Myc-PAI were con- the testes. The testes were amputated with dissecting shears and the scro-
tum sutured shut with 6-0 Ethilon black monofilament nylon (Ethicon Inc.,structed by ligation of the following gene fragments into the Bluescript (KS)
backbone (Stratagene). For PB-Flag-Myc-PAI: the poly(A) tail of the insulin 1665). A local triple antibiotic was applied over the region of the wound to
facilitate healing.receptor gene (PAI) was subcloned into the BamHI/NotI site of the bluscript
KS multiple cloning site (MCS). The 5	 flanking promoter region (
426/
28) of the rat probasin gene was subcloned into the KpnI/EcoRV restriction Pathological and immunohistochemical data
sites located in the MCS. The human Myc c-DNA was amplified by PCR Mice were aged to the appropriate time point and then sacrificed for dissec-
tion. The prostate tissues that were sent for histology were marked with inkusing a 5	 primer containing the BglII restriction site and the consensus
on one side (the cut side), splayed, and embedded “en face” to maximizesequence for the FLAG epitope (5	GGGAGATTCTCATCGCCACCATGGAC
pathologic examination of each lobe. Sections were cut in the same mannerTACAAGGACGACGACGACAAGGCCATGCCCCTCAACGTTAGCTTCACC).
on the microtome, enabling us to orient the prostatic lobes with the bladderThe epitope tag was engineered to aid with immunohistochemistry; however,
and the seminal vesicles as a reference point. Prostates, testes, lung, liver,we were unable to detect it via Western blot (data not shown) and relied on
bone (spine), kidney, and brain were all harvested for Western blot analysisthe human-specific anti-9E10 Myc antibody (Santa Cruz) to detect transgene
and histology. The tissues that were kept for protein analysis were homoge-expression. The 3	 primer contained a BamHI restriction site for cloning
nized using a tissue grinder in 2 SDS buffer (100 mM Tris-Hcl pH  6.8,purposes (3	GGGGGATCCTTACGCACAAGAGTTC CGTAGCTGTTC). After
200 mM DTT, 4% SDS, 20% glycerol, 50 mM B-gly-Phosphate, 1 mMPCR amplification, the product was gel purified, digested, and filled in using
NaVo4, and 40 g/ml PMSF) and normalized for total protein via Bio-Radthe large fragment Klenow polymerase. Following gel purification, the blunt-
assay. Tissue used for histology was fixed initially in 10% buffered formalinended product was subcloned into the EcoRV site of the bluescript KS
phosphate (Fisher SF100-4) for 8 hr followed by gentle washing in runningPB-PAI backbone, thus generating the PB-Flag-Myc-PAI transgenic con-
water and finally transferred to 70% ethanol. Serial tissue sections (4 mstruct. The ARR2PB-Flag-Myc-PAI was generated in the same way except
thick) were cut from paraffin-embedded blocks and placed on charged glassthat the ARR2PB promoter sequence was subcloned into the KpnI/EcoRV
slides. H&E and masson trichrome staining were performed using standardsite instead of the PB promoter. The ARR2PB sequence contains the original
procedures. For immunohistochemical analysis using polyclonal antibodies,probasin sequence PB (
426/28) plus two additional androgen response
the Vector Laboratories R.T.U. Vectastain Universal Elite ABC Kit (cat# PK-elements (Zhang et al., 2000a). The completed constructs were sequenced
7200) was used, and for monoclonal antibodies, we used the Vector M.O.M.and tested for promoter inducibility by androgen in LNCaP cells by transient
Basic Kit (BMK-2202). Briefly, sections were deparaffinized with xylene andtransfection before microinjection into FVB ova. By transient transfection,
rehydrated through graded alcohol washes followed by antigen retrieval inthe ARR2PB promoter was able to confer approximately 20 higher levels
a pressure cooker for 30 min in sodium citrate buffer (10 mM, pH 6.0). Slidesof expression than the PB promoter (data not shown).
were then incubated in 0.3% hydrogen peroxide to quench endogenous
horseradish peroxidase for 30 min. The slides were then blocked by incuba-Generation of transgenic ARR2PB-Myc-PAI and PB-Myc-PAI mice
tion in normal horse serum (dilution 1:20) in 0.1 M Tris-buffered saline (pHThe ARR2PB-Myc-PAI and PB-Myc-PAI constructs were linearized with KpnI/
6.0) and subsequently incubated for 30 min with the following antibodiesNotI, microinjected into fertilized FVB ova, and transplanted into a pseudo-
diluted in Tris-buffered saline: anti-synaptophysin polyclonal antibody (Dakopregnant female (University of Irvine Transgenic Facility). Transgenic found-
# A0010) diluted (1:5000), anti- smooth muscle actin monoclonal antibodyers were screened by PCR using genomic DNA isolated from tail snips. The
(Dako # M0851) diluted (1:1000), anti-Nkx3.1 polyclonal antibody (kindly5	 primer was specific to either the ARR2PB promoter (5	ARR2PB-CAATGTC
provided by Dr. Cory Abate-Shen) diluted (1:6000), anti Ki67 polyclonalTGTGTACAACTGCCAACTGGGATGC) or the PB promoter (5	PB-CCGGT
antibody (Novacastra Laboratories #NCL-Ki67p) diluted (1:20,000), anti-CGACCGGAAGCTTCCACAAGTGCATTTA), and the 3	 primer for both reac-
androgen receptor polyclonal antibody (Upstate # 06-680) diluted (1:100),tions was located at the end of the Myc cDNA (5	TTACGCACAAGAGTTC
anti-laminin polyclonal antibody (Sigma # L-9393) diluted (1:300). NegativeCGTAGCTGTTC). A PCR product of 1438 base pairs was generated from
controls were included in each assay. Slides were then treated with biotin-the ARR2PB-Myc-PAI mice and a 1774 base pair product was produced by
labeled anti-mouse IgG and incubated with preformed avidin biotin peroxi-the PB-Myc-PAI mice. Seven founder lines were obtained from the ARR2PB-
dase complex. Metal enhanced diaminobenzidine substrate was added inMyc-PAI construct (designated 1, 2, 4, 7, 8, 11, and 13) whereas three
the presence of horseradish peroxidase, and finally, sections were counter-founders were generated with the PB-Myc-PAI construct (designated # 6,
stained with hematoxylin, dehydrated, and mounted.9, 10). Breedings were carried out and germline transmission was obtained
by four ARR2PB-Myc-PAI founders (4, 7, 11, and 13) and two PB-Myc-PAI
mice (6 and 9). These mice were bred and the offspring were aged to TUNEL assays
TUNEL assays were performed as described in the In Situ Cell Death Detec-determine if prostate cancer developed in the transgene-positive male mice.
Prostates were isolated “en block” from transgenic and wild-type mice at tion Kit, POD from Roche. Prior to the addition of TdT enzyme, sections
were deparaffinized with xylene and rehydrated through graded alcohol2 to 12 weeks as well as at 6, 9, 12, and 16 months and cut in half along
the saggital plane. Superficial and deep H&E sections were examined on washes. Antigen retrieval was performed in sodium citrate buffer (10 mM,
pH 6.0) by applying microwave irradiation (750 W) for 1 min. The slides wherethe same tissue in order to document the presence/absence of mPIN, mi-
croinvasion, and invasive adenocarcinoma (described below). then incubated for 5 min in 3% hydrogen peroxide to quench endogenous
horseradish peroxidase. Next, slides were immersed for 30 min at room
temperature in Tris-HCl, 0.1 M, pH  7.5 containing 3% BSA and 20%Mouse dissections, tissue isolation, and castration
normal bovine serum. TUNEL reaction mixture containing a 1:20 dilution ofUrogenital organs were isolated and prostates were microdissected in a
TdT enzyme was added to the slides for 2 hr at 37C in a humidified atmo-petri dish containing 10 ml of cold phosphate-buffered saline (1 PBS,
sphere chamber. Fifty microliters of Converter-POD was then added to eachGibco-BRL 14190144) under a dissecting microscope. Adipose tissue sur-
slide and incubated at 37C for 45 min in a humidified atmosphere chamber.rounding the mouse prostates was cleared using forceps. The mouse pros-
DAB substrate was applied for 1 min followed by counterstaining in hema-tate is composed of four pairs of lobes (ventral, dorsal, lateral, and anterior
toxylin.lobes), which were separated from the urethra using dissecting shears. One
half was used to obtain protein and RNA while the other half was fixed in
10% phosphate-buffered formalin for histology (Fisher SF100-4). The liver, Evaluation of the vasculature
For visualization of vessels, mice received an intravascular injection of fluores-testes, bone from the spine, brain, kidneys, and lungs were also isolated
for both histological examination as well as protein analysis to check for cein isothiocyanate (FITC) labeled Lycopersicon esculentum lectin (1 mg/kg,
Vector, Burlingame, California). This lectin binds to the luminal surface of murinenonspecific expression of Myc. For castration experiments, mice were anes-
thetized using Isoflurane (Abbott Laboratories). The perineal region was vasculature. Five minutes later, the animals were fixed by perfusion of 1%
paraformaldehyde in phosphate-buffered saline (pH 7.3) at a pressure of 120cleaned three times with ethanol and a betadine scrub (VWR, AJ159778),
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mm Hg using a cannula in the left ventricle. Prostates were subsequently To determine the number of genes to use in the weighted gene voting
dissected and either mounted directly on glass slides (2 month prostates) or algorithm (step b1), we used a consistency requirement. This is necessary
embedded (12 month prostates) in low melting point agarose (BioWhittaker since the weighting factor is not perfect and using too many genes results
Molecular Applications, Rockland, Maine) and cut at 200 m sections with in the incorporation of noise. In summary, for all possible values of n (from
a Vibratome (The Vibratome Company, St. Louis, Missouri). Sections were 1 to the total number of orthologs), we used n genes to make the Myc-like
subsequently mounted onto glass slides using anti-fade media (Vectashield, and non-Myc-like assignments. In each case, we then determined what
Vector, Burlingame, California) in the presence of Topo3 dye (Molecular fraction of these n genes are significantly differentially expressed (p  0.1)
Probes, Oregon) for visualization of nuclei and examined with a BioRad1024 between the two groups (i.e., the fraction of individual genes that voted
confocal microscope (BioRad, Hercules, California). Evaluation of vascular consistently with the consensus [summed] vote of all n genes). Then for the
density was performed on a Nikon Diaphot 300 microscope equipped with final predictions, we used the value of n for which this fraction was maximal.
a Toshiba 3CCD camera. Number of vessels per 250 m square was ob- Applying this procedure individually to each dataset, the number of genes
tained by using IMAGEPRO 4.0 software (Media Cybernetics, Silver Spring, used in the weighted gene voting algorithm ranged from 10 to 50.
Maryland). To achieve comprehensive sampling, three independent animals Since the different human datasets were collected using different gene
were evaluated per age. Ten images of 250 m each were assessed per microarrays with different genes present, the human orthologs used in the
animal. Statistical significance was assessed by Student’s t test. weighted gene voting varied between datasets. It is also noteworthy that
from the genes used in the predictions, chosen only by their expression
Microarray measurements patterns in the mouse data, only one (Hs.84775) ended up on the top 10
Total RNA was isolated from gross prostate tissue following microdissection list of genes most consistently modulated in all datasets (Table 2A).
using the Tri-Reagent RNA Isolation Reagent (Sigma-Aldrich cat# T9424) as In the second method (red path), (b2) we first inferred the Myc status
described by the manufacturer. Biotin-labeled cRNA was generated follow- of human tumors based on their relative Myc expression levels, assigning
ing Affymetrix protocols. Briefly, first strand cDNA synthesis was carried out the tumors to one of two groups, Hi-Myc or Lo-Myc, based on whether their
by reverse transcribing total RNA using Superscript Reverse Transcriptase Myc expression level was above or below the mean Myc expression level
(Gibco cat# 18064-014). Second strand synthesis was performed using 10 for the dataset. Again, we preformed this step individually for each human
U/l DNA ligase (Gibco cat# 18052-019), 10 U/l DNA Pol I (Gibco cat# dataset. Steps c and d were then carried out as above. For human dataset C,
18005-025), and 2 U/l RNase H (Gibco cat# 18021-014). Double-stranded we only used samples with similar overall microarray hybridization intensities
cDNA cleanup was done using the GeneChip Sample Cleanup Module (Affy- (scale factors between 0.7 and 1.4) (Singh et al., 2002).
metrix cat# P/N 900371). Synthesis of biotin-labeled cRNA was carried out
using the Enzo Bioarray Kit (Enzo Diagnostics Inc. cat# 42655-20) and, Acknowledgments
following fragmentation, was hybridized to Affymetrix murine chips (U74Av2).
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